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INTRODUCTION
The use of allo-and xenogenic cells in regenerative therapies will always entail the possibility of graft rejection and the necessity of applying immunosuppressive therapy, which as a result will be a burden for patients. Therefore, most investigators in the field currently consider autologous cells as the most logical choice for study.
Mesenchymal stromal cells (MSC), a much used source of autologous cells, can be isolated relatively easily from multiple sources including adipose tissue, tibia, femur, lumbar spine and trabecular bone [1] [2] [3] [4] . They can be then expanded in vitro and are characterized by their multipotency. Among others they can differentiate into the adipogenic, osteogenic and chondrogenic lineages [5, 6] . What is less well documented is the ability of MSCs to differentiate towards other cell types such as skeletal muscle cells and neural cells [7] [8] [9] .
Moreover, it was shown lately that MSCs can also be a source of endothelial-like cells [10] [11] [12] , which would qualify them as candidate cells for therapies aimed at improved tissue vascularization, such as treatment of ischemic tissues and various strategies concerning large graft engineering.
We and others have shown that when human MSCs are grown in endothelial differentiation medium, they express endothelial markers such as CD31, von Willebrand factor and VEcadherin, both at the mRNA and protein level [11] [12] [13] [14] [15] [16] [17] . In addition, the actively take up acidic LDL, another hallmark of endothelial cells. When grown on Matrigel, the cells will form tube-like structures. Moreover, when these cells are implanted in immune-deficient animals, CD31 positive human cells can be seen in the vessel wall of perfused blood vessels, demonstrating that human cells can functionally contribute to blood vessels. Nevertheless, further characterization of the cells is needed, and for that reason we refer to the cells as "endothelial-like cells". This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
In order to apply MSC-derived endothelial-like cells, it is essential to establish a stable protocol for MSC isolation, culture and differentiation, because it will affect the therapeutic effect of the cells, as demonstrated previously for the application of MSCs in bone tissue engineering [18] [19] [20] . We have recently described a robust protocol to induce endothelial-like cells from bone marrow-derived MSCs in vitro and demonstrated their ability to contribute to the vasculature upon implantation in a mouse model. What remains to be addressed in order to bring endothelial-like MSCs to the clinic is both the large inter-donor variation in multilineage potential [1, 21] and the phenomenon of loss of multipotency upon culture expansion of MSCs. We and others have observed striking differences between hMSCs of different donors with regard to growth rate, expression of both lineage-specific and non-specific markers such as ALP and STRO-1 and their response to in vitro differentiation and ectopic bone formation [1, [21] [22] [23] . Similar situation can occur upon endothelial differentiation which can explain the controversy concerning the ability of MSCs to acquire endothelial characteristics. A complicating fact is that therapeutic efficacy of MSCs is often not directly linked to marker gene or protein expression in vitro [24] [25] [26] .
Because the yield of hMSCs upon isolation is very low, expansion in culture is an essential step in their application. Unfortunately, this is associated with culture-induced loss of multipotency, as described by several researchers [1, 27] . It was demonstrated that in vitro expanded MSCs acquire a phenotype characterized by loss of multipotency already at early passages [27-29] followed by replicative senescence at later stages of expansion. It appears that a hierarchy exists among the different lineages with respect to the number of population doublings at which loss of the particular differentiation route comes in effect [1, 30] .
Although donor variability and loss of multipotency has been well-described for differentiation into the osteo-and adipogenic lineages, no such data is available for endothelial-like differentiation. To address this deficiency we have created a bank of MSCs This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. isolated from 62 donors (patients that were undergoing orthopedic surgery) and collected data about their in vitro expansion and differentiation capacity as well as their gene expression profiles. Using microarray study we have identified a diagnostic bone-forming classifier [23] capable of indicating the in vivo bone-forming capacity of hMSCs from different donors (unpublished data). In this manuscript, we have selected 20 donors of this bank and evaluated their propensity to differentiate into endothelial-like cells in order to sketch inter-donor variability and to evaluate whether gene expression in undifferentiated hMSCs correlated to it. Moreover, we have studied loss of endothelial-like differentiation potential during culture expansion and compared it to loss of adipo-and osteogenic differentiation. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
MATERIALS AND METHODS

Isolation and culture
Human mesenchymal stromal cells (hMSCs) were isolated from human bone marrow from donors who provided us with written informed consent [31] . Aspirates were resuspended using a 20G needle and plated at a density 0.5 million mononucleated cells/cm 2 . Cells were grown in MSC proliferation medium which contains minimal essential medium (alfa-MEM, GIBCO) supplemented with 10% fetal bovine serum (FBS, Lonza), 100 U/ml penicillin (GIBCO), 10 g/ml streptomycin (GIBCO), 2 mM L-glutamin (GIBCO), 0.2 mM L-ascorbic acid 2-phosphate magnesium salt (ASAp, Sigma Aldrich) and 1ng/ml basic fibroblast growth factor (bFGF, Instruchemie) at 37C in a humid atmosphere with 5% CO2. Cells were expanded up to passage 2. For further experiments hMSCs from 23 different donors and one immortalized clone (iMSCs, courtesy of Ola Myklebost) were cultured in basic medium (alfa-MEM supplemented with 10% FBS, 100 U/ml penicillin, 10 g/ml streptomycin, 2 mM Lglutamin, 0.2 mM ASAp). Human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in endothelial growth medium (EGM-2, Lonza).
ALP analysis
In order to analyze the activity of alkaline phosphatase, hMSCs from one donor were seeded at a density of 5,000 cells/cm 2 in 6-well plates. Osteogenic medium (alfa-MEM, 10% FBS, 100 U/ml penicillin, 10 g/ml streptomycin, 2 mM L-glutamine, 0.2 mM ASAp, 0.01 M BGP, 10 -8 M dexamethasone) was changed twice a week and cells were cultured for 1 week.
ALP activity was analyzed using the Sigma kit #85 per manufacturer's instructions. Briefly, the culture medium was aspirated, cells were washed twice with calcium and magnesium free PBS and fixed in acetone/citrate. After washing in deionized water cells were stained with Fast Blue RR/naphthol. As a result naphthol AS-MX is liberated and immediately coupled This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
with a diazonium salt forming an insoluble, visible pigment at sites of phosphatase activity.
Cells were photographed using a Nikon SMZ 10A camera.
To confirm the results, an ALP biochemical assay (CDP-Star, Roche) was performed on selected samples. Briefly, cells were washed with PBS and lysed with lysis buffer (100mM potassium phosphate, pH 7.8, 0.2% Triton-X-100) for 10 min at room temperature. 10 l of the lysate was put in an optiplate together with 40 l of CDP-Star, incubated for 30 min in darkness at room temperature and then measured with a Victor Light Luminescence Plate
Reader (Perkin Elmer).
Adipogenesis
Adipogenic differentiation capacity of hMSCs was determined as described previously [32] .
Briefly, cells from one donor were cultured for three weeks in adipogenic medium (DMEM, 10% FBS, 100 U/ml penicillin, 10 g/ml streptomycin, 0.5 mM IBMX, 1 M dexamethasone, 10 M insulin, 200 M indomethacin). After that, lipid formation was visualized by staining with Oil red O. Cells were photographed using a Nicon Eclipse TE300 and the adipocytes were counted in the picture frame. At least 3 different locations of each well were included in the quantification.
Endothelial induction of MSCs
hMSCs from passage 3 and iMSCs from passage 25 were used for endothelial induction protocol as described previously [10] . Briefly, cells were seeded at a density of 3,000 cells/cm 2 on tissue culture plastic in EGM-2 and cultured for 10 days. After one day in static culture, shear force was applied using an orbital shaker. For induction on Matrigel, wells on 6-well plates were covered with 1 ml of growth factor reduced Matrigel (BD Bioscience) diluted 1:1 in EGM-2 without growth factors. Cells were seeded at the density of 30,000 cells 
Matrigel assay
The assay was performed as described above. The formation of capillary-like structures (CLS) on Matrigel was observed over time using an inverted microscope (Nikon Eclipse TE300). Cells from all 20 donors were used in this study. Pictures were taken at different time points (4, 8, 16, 24, 48 , and 96 hours after seeding) using a Nikon DS-L2 camera. The experiment was performed in triplicate.
TubeCount
Capillary-like structure formation was quantified based on images taken at a 24-hour time point using TubeCount software, as described previously [10] . As a result we gathered valuable statistics such as total and average tube length, average tube width, number of tube branching points and total tube area. A minimal number of 3 pictures per condition were analyzed.
RNA isolation and quantitative PCR
Total RNA was isolated using TRIZOL reagent according to manufacturer's protocol. In short, 1 ml of Trizol reagent was added per T25 flask (cells cultured in basic medium) or per well (cells cultured on Matrigel in 6-well plates). Samples were incubated for 5 min at room temperature to allow complete dissociation, and phase separation was performed by adding chloroform. After that samples were centrifuged at 12,000 x g for 15 min. RNA was precipitated by mixing the aqueous phase with isopropyl alcohol followed by 10 min This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
incubation at room temperature. Samples were centrifuged again and the remaining RNA pellet was washed with 75% ethanol. The obtained samples were dissolved in water, and after that the quantity and quality of RNA was analyzed using spectrophotometry (ND-1000 spectrophotometer). OD 260/280 nm ratios >1.8 were observed for all samples indicating high purity.
500 ng of RNA was used for first strand cDNA synthesis using Superscript II (Invitrogen)
according to the manufacturer's protocol. One µl of 3x diluted cDNA was used for PCRs 
Microarray analysis
To analyse the gene expression profile of hMSCs, microarray analysis was used. RNA was hybridized to the Human Genome U133A 2.0 Array (Affymetrix) and scanned with a GeneChip G3000 scanner (Affymetrix). To normalize the measurements, we used a normalization method which removes hybridization, amplification and array location based technical effects. Further data analysis and statistical testing were performed using R and This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
used to determine differential gene expression. To analyse the donor variation in terms of endothelial differentiation ability, we scored the different donor-derived MSCs based on their CD31 expression on one hand and KDR expression on the other hand. Subsequently, a list of genes ranked on fold change between the best and poorest endothelial differentiating donors was generated.
Statistics
Each experiment was performed in triplicate. Data that required multiple comparison test was analyzed in SPSS (PASW statistics) using one-way Anova followed by Tukey's multiple comparison test (P<0.05). Error bars on graphs represent standard deviation.
Ethics statement
Human mesenchymal stromal cells (hMSCs) were isolated from human bone marrow from donors with written informed consent. This study was carried out in strict accordance with the recommendations of the Medisch Ethische Toetsings Commissie Twente (Medical Ethical
Research Committee Twente) and was approved by this Committee. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
RESULTS
hMSC characterization
hMSC from our bank of 62 donors have been characterized previously (unpublished data)
according to the set of standards proposed by the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy [35] . In this manuscript, we have randomly selected 20 donors from the donor bank [1] . After defrosting and brief expansion, a subsection of cells of all donors were subjected to osteogenic and adipogenic differentiation.
As shown in Supplementary Fig 1, MSCs from all donors readily acquired properties of adipocytes or osteoblast respectively, demonstrating their multipotency.
Effect of culture expansion on multipotency of hMSCs
We previously showed [1] that efficient differentiation of hMSCs is limited after prolonged expansion in vitro. To confirm these results, osteogenic and adipogenic differentiation of hMSCs from one donor was evaluated over 10 passages. Similar to previous observations, changes in cell morphology occurred during prolonged in vitro expansion ( Fig 1A) . hMSCs between passage 7 and 10 lost their fibroblast-like shape and acquired a more spread morphology. The cells in culture became larger, with irregular and heterogeneous contours.
Moreover, hMSCs expanded in vitro lost their proliferation capacity over time, being unable to reach confluency even after prolonged culture (data not shown).
To document osteogenesis, we measured dexamethasone-induced activity of the bone-maker alkaline phosphatase (ALP) [1] . Cells from passage 1 showed a 3 times higher activity of ALP than cells from passage 2 to 5 ( Fig 1B) and ALP activity declined again three-fold in cells from passage 6 and higher ( Fig 1B) . A similar trend was observed for adipogenic differentiation (Fig 2A) , where cells from passage 1 differentiated more efficiently than cells from passage 2 to 7. A gradual loss of adipogenic potential was observed ( Fig 2B) . Next, we evaluated whether the endothelial differentiation capacity of hMSCs was lost as well upon culture expansion. In this case, we expanded cells from 2 donors (D42, D56) and first looked at their capacity to form tubes on Matrigel (Fig 3A) . Overall, MSCs did not lose their capacity to form tubes, up to passage 7. At higher passages, we were unable to retrieve sufficient number of cells to perform the assay. In the case of donor 42, prolonged expansion led to shorter capillary-like structures, although the number of branching points seemed to increase.
With cells from donor 56, we observed the opposite, with longer capillary like structure and fewer branching point at high passages. As a second readout of endothelial differentiation, we measured the expression of the endothelial marker CD31 in hMSCs exposed to proliferation medium and endothelial differentiation medium of three donors at various passage numbers.
At passage 3, we observed induction of CD31 in all three donors, but this was completely lost in donor 57 . Surprisingly, the cells of the other two donors were still able to induce CD31 expression at passage 7, and even with a higher fold induction than at passage 3 ( Fig 3B) . Our data show that endothelial differentiation is not as sensitive to culture-induced loss of differentiation capacity as adipogenic and osteogenic differentiation are.
Endothelial differentiation of hMSCs
To investigate whether hMSC source (donor) influences endothelial differentiation, capillarylike structure formation was observed on Matrigel. Tube formation was recorded by phase contrast microscopy and pictures were used for further study. As shown in Fig 4A, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
inter-donor variation was seen, ranging from equal efficiency as HUVECS to donors of whom the cells produced five-fold less tubes. It also occurred to us that cells from some donors started to form capillary-like structures at a later time point than most, but in the end reached the same level of CLS formation (data not shown). Overall, the total tube length and the number of branching points correlated to each other. Since all results were taken at an arbitrarily chosen time point (24h) identical in case of all analyzed samples, this variability is present in the final quantification. Taken together, our data shows that cells from all donors responded to the Matrigel stimulation but with different efficiency. Yet, there was not a single donor from whom the cells did not respond at all.
Endothelial gene expression profile in MSCs
For further classification of EL-MSCs from different donors we analyzed endothelial-specific genes expression. As previously, cells were cultured for 10 days in EGM-2 on an orbital shaker and were then reseeded on Matrigel for another 24 hours. This relative short time of culture was chosen because in some cases, the Matrigel coating was completely resorbed at later time points, indicating donor specific matrix degrading activity. We performed qPCR on platelet endothelial cell adhesion molecule (CD31), vascular endothelial growth factor receptor 2 (KDR), von Willebrand factor (vWF) and vascular endothelial Cadherin (VECadherin) and expressed it relative to GAPDH. We found a great variability of endothelial marker induction in cells from different donors. Cells from all donors responded to the differentiation protocol with increased CD31 expression (Fig 5A) , with a fold induction between 3 and 78. In fifteen donors out of twenty we observed increased KDR expression (fold induction between 16 and 1000) and twelve of the 20 donors showed increased vWF expression (fold induction between 2 and 18) (Fig 5B and 5C ). Only six donors responded with significantly increased VE-Cadherin expression (fold induction between 32 and 88) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
( Fig 5D) . Not in all donors VE-cadherin expression was matched by other markers and we did not observe a robust correlation between total tube length or number of branching points and endothelial marker expression. The expression levels of all tested endothelial markers except KDR did not reach the level of its expression in HUVECs, however, we confirmed in our previous study with immunostainings [16] , that these expression levels were relevant.
For further analysis we divided twenty donors into four groups, scoring their endothelial differentiation capability based on changes in CD31 and KDR expression: 25% of worst performing donors received grade 1, next 25% grade 2, third group grade 3 and the best performing 25% donors received grade 4 (Supplementary Table 1 ). These groups of samples allowed to discriminate between bone marrow-derived hMSCs able to differentiate efficiently into the endothelial lineage (grade 4) from hMSCs that do not have this differentiation capacity (grade 1) and were further used to find differences in gene expression of hMSCs at proliferating state.
Correlation between gene expression profile and ability to show endothelial gene expression
We investigated whether the differential expression of marker genes in endothelial-like cells is reflected in the gene expression repertoire of their undifferentiated ancestors, in other words we tried to find genes predictive of the efficacy of induction of endothelial marker gene expression. To this end, we compared the expression profiles of MSCs between the four different groups defined above. The top 30 genes from the resulting list were ranked on p value (Table 1) . Interestingly, among the listed genes we found three that are directly system development and diseases: ELN, CRYAB, SLC5A3, CA12, PHLDA1, FHL1 (Table   2 ). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. In this study we isolated and characterized hMSCs from 20 independent donors. First we analyzed cell performance in a Matrigel assay where we found that the efficiency in tube formation was not the same between different donors. According to our observations at various time points (data not shown), some of the differences in results could be caused by the chosen observation time that was set for 24 hours after seeding. Since cells from different donors started to form CLSs at different time points, the results were not fully reflecting the absolute potential of hMSCs to form CLSs. The differences between donors occurred rather as a result of differences in the speed of attachment and migration. CLS network formation on Therefore, for microarray studies we decided to focus on these two genes, namely CD31 and KDR, which are commonly used as endothelial markers and for which up-regulation occurred in most of the donors.
DISCUSSION
Based on the performed microarray study we selected 30 genes that were differentially expressed. Among those we identified 17 genes whose expression is involved in VEGF This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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